^
    1d
    Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids (clinicaltrials.gov)
    P1/2, N=10, Terminated, Masonic Cancer Center, University of Minnesota | N=55 --> 10 | Trial completion date: Sep 2028 --> Feb 2026 | Suspended --> Terminated | Trial primary completion date: Sep 2026 --> Feb 2026; Sponsor terminated financial support
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Jakafi (ruxolitinib) • prednisone • methylprednisolone sodium succinate
    3d
    Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) (clinicaltrials.gov)
    P3, N=95, Recruiting, Incyte Corporation | N=68 --> 95
    Enrollment change
    8d
    CONTINUUM-GVHD: Gecacitinib in the Treatment of Steroid-Refractory/Dependent Chronic Graf Versus Host Disease (cGVHD). (clinicaltrials.gov)
    P1/2, N=33, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P1/2 trial
    9d
    Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome (clinicaltrials.gov)
    P2, N=70, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    PDGFRA (Platelet Derived Growth Factor Receptor Alpha) • PDGFRB (Platelet Derived Growth Factor Receptor Beta) • FIP1L1 (Factor Interacting With PAPOLA And CPSF1)
    |
    imatinib • Jakafi (ruxolitinib)
    12d
    Integrative In Silico Multi-Omics Profiling of circRNA-Mediated ceRNA Networks Reveals Prognostic Biomarkers and Repurposed Therapeutic Candidates in Gastric Cancer. (PubMed, Int J Mol Sci)
    To explore therapeutic implications, transcriptomics-guided drug repositioning combined with molecular docking analysis identified five candidate compounds-celastrol, fedratinib, pevonedistat, tozasertib, and withaferin A-predicted to target key network hubs. Overall, this in silico study provides a ceRNA-centered regulatory framework for GC and prioritizes biologically informed biomarkers and repositioned drug candidates with potential applicability across other malignancies to converge precision oncology.
    Journal
    |
    TGM2 (Transglutaminase 2) • COL4A1 (Collagen Type IV Alpha 1 Chain) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) • MMP14 (Matrix Metallopeptidase 14)
    |
    pevonedistat (MLN4924) • Inrebic (fedratinib) • tozasertib (MK-0457)
    12d
    Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) (clinicaltrials.gov)
    P3, N=550, Recruiting, Incyte Corporation | N=98 --> 550
    Enrollment change • Trial initiation date
    12d
    CONTINUUM-MF: Gecacitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China
    New P2 trial
    13d
    A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS) (clinicaltrials.gov)
    P2, N=78, Recruiting, Swedish Orphan Biovitrum | Active, not recruiting --> Recruiting
    Enrollment open
    |
    Vonjo (pacritinib)
    13d
    Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia (clinicaltrials.gov)
    P2, N=20, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Jun 2027 --> Dec 2027 | Trial primary completion date: Jun 2027 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Jakafi (ruxolitinib) • sirolimus • fludarabine IV • cyclosporin A microemulsion
    13d
    De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis (clinicaltrials.gov)
    P2, N=56, Active, not recruiting, Medical College of Wisconsin | Suspended --> Active, not recruiting
    Enrollment closed
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • cyclophosphamide
    14d
    AALL1521: A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=171, Completed, Incyte Corporation | Active, not recruiting --> Completed
    Trial completion
    |
    JAK2 (Janus kinase 2) • CRLF2 (Cytokine Receptor Like Factor 2) • JAK1 (Janus Kinase 1) • IL7R (Interleukin 7 Receptor) • EPOR (Erythropoietin Receptor) • SH2B3 (SH2B Adaptor Protein 3)
    |
    cytarabine • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide • vincristine • prednisone • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • Erwinase (erwinia asparaginase)
    14d
    POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib. (PubMed, Future Oncol)
    Study objectives are to isolate the contribution of add-on navtemadlin by assessing SVR and TSS 24-weeks after randomization from the pre-randomization baseline and to demonstrate that this contribution is clinically meaningful using established SVR and TSS endpoints from the pre-ruxolitinib treatment baseline. Secondary endpoints include progression-free survival, leukemia-free survival, and OS.Clinical Trial Registration: NCT06479135 (ClinicalTrials.gov); EUCT 2023-504724-25-00 (EUClinicalTrials.EU).
    Clinical • P3 data • Journal
    |
    CD34 (CD34 molecule)
    |
    TP53 wild-type
    |
    Jakafi (ruxolitinib) • navtemadlin (KRT-232)